×

AAN2026 Desclating High Efficacy DMT

Tweet I have been critical of neuros for using the escalating apporach to DMT and you us a higher efficacy drug after the failure of treatment. A strategy based on failure was always a flawed approach and you paid the price for reluctance of neuros/nurses…

Another BTKi for MS?

Tweet Recently we were talking about the hare and the tortoise and the first hares related to bruton tyrosine kinase irreversible inhibitors failed to beat teriflunomide in trials in relapsing MS. We then heard an reversible inhibitor was active and at that point I asked…

The reality of MS fatigue and its impact on daily life

Rafael Lara, who goes by Macho, shares his experience living with multiple sclerosis fatigue, including how it affects his daily routines, energy levels, and ability to spend quality time with his family while navigating life with MS. The post The reality of MS fatigue and…

AAN 2026: Fenebrutinib outperforms Aubagio for treating relapsing MS

The experimental drug fenebrutinib was shown to significantly outperform Aubagio (teriflunomide), an approved therapy, in reducing relapses and MRI markers of disease activity in people with relapsing forms of multiple sclerosis (MS). That’s according to new data from a pair of largely identical Phase 3…

Scientists studying yak genetics discover myelin repair mechanism

A team of scientists in China, attempting to understand the function of a genetic mutation commonly found in animals living at high altitudes, discovered a previously unknown mechanism key to myelin repair. The discovery could have important implications for diseases such as multiple sclerosis (MS),…

Bloody Statistics..And Alemtuzumab

Tweet I have been taken to task out my slipshod use of statistics and suggested about 50% get disease control after two doses and about 50% after three doses so that with three doses about 75% of people get control. Yep I have not referenced…